Pivoting the Pathway
With an increasing prevalence of kidney cancer during the past decade, several pharmaceutical manufacturers are stepping up to the plate with potentially monumental treatments.
Specifically, targeted therapies have paved the way in prolonging survival in patients with advanced or metastatic renal cell carcinoma compared to the previous treatment of interferon-alfa and interleukin-2. There are currently seven FDA approved targeted therapies in the market with a handful of new targeted agents quickly moving through the pipeline. Both Exelixis’ Cabozantinib and Eisai’s Lenvatinib have been granted a breakthrough therapy designation by the FDA. The targeted therapies market is potentially being challenged by immunotherapies called checkpoint inhibitors. Bristol-Myers Squibb’s Nivolumab, used as monotherapy or in combination with Ipilmumab and Merck’s Pembrolizumab are progressing through trials and could change the pathway of kidney cancer treatments.Kidney Cancer Market Access
The market access snapshot for three FDA approved targeted therapies is a sample of the information that can reveal some of the key trends in this market basket. From preferred to heavily restricted statuses, there is an extensive variety in access across geographies. Reach out to our team to learn more about the chart above.
Due to resistance with monotherapies, there is a push to investigate combination therapies in hopes of further prolonging patient survival. On the horizon, Tracon’s TRC-105 combined with Axitinib square off with the blend of Roche’s MPDL3280A and Bevacizumab. Notably, cancer vaccines such as Immatics’ IMA-901 and Argos’ AGS-003 are looking to help stimulate growth in the kidney cancer drug market.
The kidney cancer drug pipeline will continue to have a consistent flow of new drugs entering the market through coming years. It is unclear which treatments will take the spotlight but it will be crucial to keep a close eye on the market access in this class.
Staying Ahead of the Curve
What tools do you have to monitor the market landscape and the utilization management techniques being employed by health plans and PBMs?
MMIT will equip your organization with class-specific data and analytics to provide a picture of the current market and to enable you to monitor changes as they occur. MMIT’s in-house team of pharmacists structures critical data about how kidney cancer therapies are managed and covered from complex, narrative policies on an ongoing basis.
We help companies understand their brand’s market access and competitive position in the kidney cancer marketplace and can help put your organization ahead of the curve.